Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00165048
Status:
UNKNOWN
Last Update Posted:
2005-12-09
First Post:
2005-09-12
Brief Title:
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial
Status:
UNKNOWN
Status Verified Date:
2005-09
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the effect of selective COX-II inhibitor in patients with regionally disseminated stomach cancer treated by palliative resection so called R1 or R2 gastrectomy
Detailed Description:
Cyclo-oxygenase COX is a family of enzymes regulating the conversion of arachidonic acid to prostaglandins COX-II is an inducible enzyme which expresses excessively when there are stimuli such as inflammation or hypergastrinaemia Up to 40 of patients with stomach cancer are found to have disseminated disease during surgical exploration While palliative resection could offer a marginal benefit in the survival of these patients almost all patients will die of progression of disease within a short time span Palliative chemotherapy has been used in the past However there is no evidence that the chemotherapy can confer any survival advantages and the side-effects and toxicity of the treatment may indeed compromise the quality of life of these patients With a better understanding of the relation between COX-II and stomach cancer it may be possible to suppress the progression of the residual cancer cells after the palliative resection by giving the patients selective COX-II inhibitors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None